Protocol Ledger

NCT06559163 · Phase II · ACTIVE NOT RECRUITING

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

Interventional Phase II clinical trial protocol NCT06559163 sponsored by Zenas BioPharma (USA) in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-17 Enrollment: 190 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06559163
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)190 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06559163
Protocol FieldVerified Registry Value
NCT IdentifierNCT06559163
Consolidated Lead SponsorZenas BioPharma (USA)
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment190 participants (ACTUAL)
Registered Start Date2024-09-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI